Filamin A interacting protein 1-like inhibits WNT signaling and MMP expression to suppress cancer cell invasion and metastasis

International Journal of Cancer

Volumn 135, Issue 1, 2014, Pages 48-60

  Kwon, Mijung ^a   Lee, Soo Jin ^a   Wang, Yarong ^a   Rybak, Yevangelina ^a   Luna, Alex ^a   Reddy, Srilakshmi ^a   Adem, Asha ^a   Beaty, Brian T ^a   Condeelis, John S ^a   Libutti, Steven K ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

FILIP1L; invasion; metastasis; MMP; WNT

Indexed keywords

FILIP1L; INVASION; METASTASIS; MMP; WNT;

BETA CATENIN; CARRIER PROTEINS; CELL LINE, TUMOR; CYTOSKELETAL PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; WNT SIGNALING PATHWAY;

EID: 84899435397     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28662     Document Type: Article

References (63)

1. Bravo-Cordero JJ, Hodgson L, Condeelis J,. Directed cell invasion and migration during metastasis. Curr Opin Cell Biol 2012; 24: 277-83.
2. Kwon M, Hanna E, Lorang D, et al. Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy. Cancer Res 2008; 68: 7332-41.
3. Burton ER, Gaffar A, Lee SJ, et al. Downregulation of Filamin A interacting protein 1-like is associated with promoter methylation and induces an invasive phenotype in ovarian cancer. Mol Cancer Res 2011; 9: 1126-38.
4. Kwon M, Lee SJ, Reddy S, et al. Down-regulation of filamin A interacting protein 1-like is associated with promoter methylation and an invasive phenotype in breast, colon, lung and pancreatic cancers. PLoS One 2013; 8 (12): e82620.
5. Desotelle J, Truong M, Ewald J, et al. CpG island hypermethylation frequently silences FILIP1L isoform 2 expression in prostate cancer. J Urol 2013; 189: 329-35.
6. Xie C, Gou ML, Yi T, et al. Efficient inhibition of ovarian cancer by truncation mutant of FILIP1L gene delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels. Hum Gene Ther 2011; 22: 1413-22.
7. Mok SC, Wong KK, Chan RK, et al. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol 1994; 52: 247-52.
8. Matei D, Graeber TG, Baldwin RL, et al. Gene expression in epithelial ovarian carcinoma. Oncogene 2002; 21: 6289-98.
9. Quaye L, Dafou D, Ramus SJ, et al. Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. Hum Mol Genet 2009; 18: 1869-78.
10. Notaridou M, Quaye L, Dafou D, et al. Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Int J Cancer 2011; 128: 2063-2074.
11. Schwarze SR, DePrimo SE, Grabert LM, et al. Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. J Biol Chem 2002; 277: 14877-83.
12. Poole LJ, Yu Y, Kim PS, et al. Altered patterns of cellular gene expression in dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus. J Virol 2002; 76: 3395-420.
13. Keese CR, Bhawe K, Wegener J, et al. Real-time impedance assay to follow the invasive activities of metastatic cells in culture. Biotechniques 2002; 33: 842-4, 6, 8-50.
14. Wyckoff JB, Segall JE, Condeelis JS,. The collection of the motile population of cells from a living tumor. Cancer Res 2000; 60: 5401-4.
15. Caswell PT, Spence HJ, Parsons M, et al. Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev Cell 2007; 13: 496-510.
16. Carpenter AE, Jones TR, Lamprecht MR, et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 2006; 7: R100.
17. Yamaguchi H, Lorenz M, Kempiak S, et al. Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J Cell Biol 2005; 168: 441-52.
18. Saxena NK, Sharma D, Ding X, et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 2007; 67: 2497-507.
19. Wang HS, Hung Y, Su CH, et al. CD44 cross-linking induces integrin-mediated adhesion and transendothelial migration in breast cancer cell line by up-regulation of LFA-1 (alpha L beta2) and VLA-4 (alpha4beta1). Exp Cell Res 2005; 304: 116-26.
20. Even-Ram S, Yamada KM,. Cell migration in 3D matrix. Curr Opin Cell Biol 2005; 17: 524-32.
21. Song Y, Yang QX, Zhang F, et al. Suppression of nasopharyngeal carcinoma cell by targeting beta-catenin signaling pathway. Cancer Epidemiol 2012; 36: e116-e121.
22. Denys H, De Wever O, Nusgens B, et al. Invasion and MMP expression profile in desmoid tumours. Br J Cancer 2004; 90: 1443-9.
23. Valenta T, Hausmann G, Basler K,. The many faces and functions of beta-catenin. EMBO J 2012; 31: 2714-36.
24. Railo A, Pajunen A, Itaranta P, et al. Genomic response to Wnt signalling is highly context-dependent-evidence from DNA microarray and chromatin immunoprecipitation screens of Wnt/TCF targets. Exp Cell Res 2009; 315: 2690-704.
25. Ueno S, Weidinger G, Osugi T, et al. Biphasic role for Wnt/beta-catenin signaling in cardiac specification in zebrafish and embryonic stem cells. Proc Natl Acad Sci USA 2007; 104: 9685-90.
26. Mazzanti CM, Tandle A, Lorang D, et al. Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells. Genome Res 2004; 14: 1585-93.
27. Hanai J, Gloy J, Karumanchi SA, et al. Endostatin is a potential inhibitor of Wnt signaling. J Cell Biol 2002; 158: 529-39.
28. Hu Y, Mivechi NF,. Promotion of heat shock factor Hsf1 degradation via adaptor protein filamin A-interacting protein 1-like (FILIP-1L). J Biol Chem 2011; 286: 31397-408.
29. Huang P, Senga T, Hamaguchi M,. A novel role of phospho-beta-catenin in microtubule regrowth at centrosome. Oncogene 2007; 26: 4357-71.
30. Hadjihannas MV, Bruckner M, Behrens J,. Conductin/axin2 and Wnt signalling regulates centrosome cohesion. EMBO Rep 2010; 11: 317-24.
31. Fuentealba LC, Eivers E, Geissert D, et al. Asymmetric mitosis: unequal segregation of proteins destined for degradation. Proc Natl Acad Sci USA 2008; 105: 7732-7.
32. Badano JL, Teslovich TM, Katsanis N,. The centrosome in human genetic disease. Nat Rev Genet 2005; 6: 194-205.
33. Bahmanyar S, Kaplan DD, Deluca JG, et al. beta-Catenin is a Nek2 substrate involved in centrosome separation. Genes Dev 2008; 22: 91-105.
34. Gerdes JM, Liu Y, Zaghloul NA, et al. Disruption of the basal body compromises proteasomal function and perturbs intracellular Wnt response. Nat Genet 2007; 39: 1350-60.
35. Wigley WC, Fabunmi RP, Lee MG, et al. Dynamic association of proteasomal machinery with the centrosome. J Cell Biol 1999; 145: 481-90.
36. Choi JW, Ahn SE, Rengaraj D, et al. Matrix metalloproteinase 3 is a stromal marker for chicken ovarian cancer. Oncol Lett 2011; 2: 1047-51.
37. Zhao H, Yang Z, Wang X, et al. Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of E-cadherin. Exp Mol Med 2012; 44: 633-41.
38. Chakravarty D, Roy SS, Babu CR, et al. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res 2011; 17: 2250-9.
39. Chou CH, Teng CM, Tzen KY, et al. MMP-9 from sublethally irradiated tumor promotes Lewis lung carcinoma cell invasiveness and pulmonary metastasis. Oncogene 2012; 31: 458-68.
40. Naiki T, Asamoto M, Toyoda-Hokaiwado N, et al. Organ specific Gst-pi expression of the metastatic androgen independent prostate cancer cells in nude mice. Prostate 2012; 72: 533-41.
41. Schmalfeldt B, Prechtel D, Harting K, et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001; 7: 2396-404.
42. Lengyel E, Schmalfeldt B, Konik E, et al. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 2001; 82: 291-8.
43. Logan CY, Nusse R,. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004; 20: 781-810.
44. Lai SL, Chien AJ, Moon RT,. Wnt/Fz signaling and the cytoskeleton: potential roles in tumorigenesis. Cell Res 2009; 19: 532-45.
45. Tetsu O, McCormick F,. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-6.
46. Sansom OJ, Reed KR, Hayes AJ, et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev 2004; 18: 1385-90.
47. van de Wetering M, Sancho E, Verweij C, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 241-50.
48. Dufour A, Overall CM,. Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol Sci 2013; 34: 233-42.
49. Amin N, Vincan E,. The Wnt signaling pathways and cell adhesion. Front Biosci 2012; 17: 784-804.
50. Kurayoshi M, Oue N, Yamamoto H, et al. Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res 2006; 66: 10439-48.
51. Matsumoto S, Fumoto K, Okamoto T, et al. Binding of APC and dishevelled mediates Wnt5a-regulated focal adhesion dynamics in migrating cells. EMBO J 2010; 29: 1192-204.
52. Weeraratna AT, Jiang Y, Hostetter G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002; 1: 279-88.
53. Badiglian Filho L, Oshima CT, De Oliveira Lima F, et al. Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Oncol Rep 2009; 21: 313-20.
54. Huang CL, Liu D, Nakano J, et al. Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor-an expression in non-small-cell lung cancer. J Clin Oncol 2005; 23: 8765-73.
55. Pukrop T, Klemm F, Hagemann T, et al. Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proc Natl Acad Sci USA 2006; 103: 5454-9.
56. Hanaki H, Yamamoto H, Sakane H, et al. An anti-Wnt5a antibody suppresses metastasis of gastric cancer cells in vivo by inhibiting receptor-mediated endocytosis. Mol Cancer Ther 2012; 11: 298-307.
57. Dwyer MA, Joseph JD, Wade HE, et al. WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an autocrine manner to increase cancer cell migration. Cancer Res 2010; 70: 9298-308.
58. Uysal-Onganer P, Kawano Y, Caro M, et al. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer 2010; 9: 55.
59. Mochmann LH, Bock J, Ortiz-Tanchez J, et al. Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG. Oncogene 2011; 30: 2044-56.
60. Dubeau L,. The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008; 9: 1191-7.
61. Boyer A, Goff AK, Boerboom D,. WNT signaling in ovarian follicle biology and tumorigenesis. Trends Endocrinol Metab 2010; 21: 25-32.
62. Rask K, Nilsson A, Brannstrom M, et al. Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. Br J Cancer 2003; 89: 1298-304.
63. Gatcliffe TA, Monk BJ, Planutis K, et al. Wnt signaling in ovarian tumorigenesis. Int J Gynecol Cancer 2008; 18: 954-62.